Merkel Cell Carcinoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Merkel Cell Carcinoma – Pipeline Review, H2 2016’, provides an overview of the Merkel Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma

The report reviews pipeline therapeutics for Merkel Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Merkel Cell Carcinoma therapeutics and enlists all their major and minor projects

The report assesses Merkel Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Merkel Cell Carcinoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Merkel Cell Carcinoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc

Apcure SAS

BeiGene Ltd

Immune Design Corp

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

NantKwest Inc

Novartis AG

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Merkel Cell Carcinoma Overview 7

Pipeline Products for Merkel Cell Carcinoma - Overview 8

Pipeline Products for Merkel Cell Carcinoma - Comparative Analysis 9

Merkel Cell Carcinoma - Therapeutics under Development by Companies 10

Merkel Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes 11

Merkel Cell Carcinoma - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Merkel Cell Carcinoma - Products under Development by Companies 15

Merkel Cell Carcinoma - Products under Investigation by Universities/Institutes 16

Merkel Cell Carcinoma - Companies Involved in Therapeutics Development 17

Amgen Inc 17

Apcure SAS 18

BeiGene Ltd 19

Immune Design Corp 20

Merck & Co Inc 21

Merck KGaA 22

Millennium Pharmaceuticals Inc 23

NantKwest Inc 24

Novartis AG 25

OncoSec Medical Inc 26

Oncovir Inc 27

Ono Pharmaceutical Co Ltd 28

Merkel Cell Carcinoma - Therapeutics Assessment 29

Assessment by Monotherapy Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

aNK Program - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

APC-001 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

avelumab - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

BGBA-317 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

DNA IL-12 - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

EBC-46 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

G-100 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

nivolumab - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

pasireotide - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

pazopanib hydrochloride - Drug Profile 95

Product Description 95

Mechanism Of Action 95

R&D Progress 95

pembrolizumab - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Poly-ICLC - Drug Profile 139

Product Description 139

Mechanism Of Action 139

R&D Progress 139

sapanisertib - Drug Profile 142

Product Description 142

Mechanism Of Action 142

R&D Progress 142

talimogene laherparepvec - Drug Profile 145

Product Description 145

Mechanism Of Action 145

R&D Progress 145

Vaccine to Target WT1 for Oncology - Drug Profile 151

Product Description 151

Mechanism Of Action 151

R&D Progress 151

Merkel Cell Carcinoma - Product Development Milestones 152

Featured News & Press Releases 152

Nov 29, 2016: FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review 152

Nov 14, 2016: NantKwest Announces Achievement of End Point in Merkel Cell Carcinoma Phase II Trial With Evidence of Efficacy of Activated Natural Killer (aNK) Cells in Solid Tumors 153

Oct 31, 2016: European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma 153

Sep 28, 2016: Merck to Present Data on Avelumab at ESMO 2016 154

Appendix 156

Methodology 156

Coverage 156

Secondary Research 156

Primary Research 156

Expert Panel Validation 156

Contact Us 156

Disclaimer 157

List of Tables

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H2 2016 8

Number of Products under Development for Merkel Cell Carcinoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Merkel Cell Carcinoma – Pipeline by Amgen Inc, H2 2016 17

Merkel Cell Carcinoma – Pipeline by Apcure SAS, H2 2016 18

Merkel Cell Carcinoma – Pipeline by BeiGene Ltd, H2 2016 19

Merkel Cell Carcinoma – Pipeline by Immune Design Corp, H2 2016 20

Merkel Cell Carcinoma – Pipeline by Merck & Co Inc, H2 2016 21

Merkel Cell Carcinoma – Pipeline by Merck KGaA, H2 2016 22

Merkel Cell Carcinoma – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 23

Merkel Cell Carcinoma – Pipeline by NantKwest Inc, H2 2016 24

Merkel Cell Carcinoma – Pipeline by Novartis AG, H2 2016 25

Merkel Cell Carcinoma – Pipeline by OncoSec Medical Inc, H2 2016 26

Merkel Cell Carcinoma – Pipeline by Oncovir Inc, H2 2016 27

Merkel Cell Carcinoma – Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 28

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Stage and Target, H2 2016 31

Number of Products by Stage and Mechanism of Action, H2 2016 33

Number of Products by Stage and Route of Administration, H2 2016 35

Number of Products by Stage and Molecule Type, H2 2016 37

List of Figures

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, H2 2016 8

Number of Products under Development for Merkel Cell Carcinoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 13

Assessment by Monotherapy Products, H2 2016 29

Number of Products by Top 10 Targets, H2 2016 30

Number of Products by Stage and Top 10 Targets, H2 2016 30

Number of Products by Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 32

Number of Products by Routes of Administration, H2 2016 34

Number of Products by Stage and Routes of Administration, H2 2016 34

Number of Products by Molecule Types, H2 2016 36

Number of Products by Stage and Molecule Types, H2 2016 36

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports